

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for reference only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



Phancy Group Co., Ltd.
範式智能技術集團股份有限公司

*(Formerly known as “北京第四範式智能技術股份有限公司 Beijing Fourth Paradigm Technology Co., Ltd.”)
(A joint stock company incorporated in the People’s Republic of China with limited liability)*

(Stock code: 6682)

- (1) PROPOSED INITIAL PUBLIC OFFERING OF RENMINBI ORDINARY SHARES (A SHARES) AND LISTING ON THE CHINEXT MARKET OF THE SHENZHEN STOCK EXCHANGE;**
- (2) ESTABLISHMENT OF THE STRATEGY COMMITTEE OF THE BOARD;**
- (3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND PROPOSED AMENDMENTS/ FORMULATION OF INTERNAL GOVERNANCE POLICIES, REVISION OF RULES OF PROCEDURES OF SPECIALISED COMMITTEES UNDER THE BOARD; AND**
- (4) OTHER RESOLUTIONS IN RELATION TO THE PROPOSED A SHARE OFFERING**

I. PROPOSED INITIAL PUBLIC OFFERING OF RENMINBI ORDINARY SHARES (A SHARES) AND LISTING ON THE CHINEXT MARKET OF THE SHENZHEN STOCK EXCHANGE

The Board is pleased to announce that, the Company plans to apply for the initial public offering of Renminbi ordinary shares (A Shares) and listing on the ChiNext Market of the Shenzhen Stock Exchange. The type of shares to be issued under the Offering is Renminbi ordinary shares (A Shares), with a par value of RMB1.00 each, and the place of listing is the ChiNext Market of the Shenzhen Stock Exchange. The basic issuance plan is as follows:

Type of shares: Renminbi ordinary shares (A Shares);

Par value per share: RMB1.00;

Number of shares to be issued:

The total number of Renminbi ordinary shares proposed to be publicly issued under this issuance shall be not less than 62.032515 million shares and not more than 186.097544 million shares (excluding the additional Shares to be issued upon the exercise of the over-allotment option), representing not less than 10% and not more than 25% of the total share capital after the issuance (including Treasury Shares). The issuance by the Company will consist entirely of new shares, and the existing Shareholders will not publicly offer any shares for sale. The Company and the sponsor (lead underwriter) may exercise the over-allotment option, and the number of A Shares issued upon exercise of the over-allotment option shall not exceed 15% of the number of shares under the proposed A Share Offering (before exercise of the over-allotment option).

The final number of shares to be issued shall be determined by the Board or its authorised persons as authorised by the general meeting, in consultation with the sponsor (lead underwriter), having regard to the number approved and registered by the competent authorities, the Company's capital requirements and market conditions;

Pricing method:

The pricing method for this issuance shall be determined by the Company and the sponsor (lead underwriter) through consultation based on the preliminary price inquiry results from offline investors, or by such other methods as recognised by China Securities Regulatory Commission ("CSRC") or the Shenzhen Stock Exchange;

Issuance method:

The issuance shall be conducted by a combination of targeted placing to strategic investors, inquiry-based placing to offline investors and online fixed-price issuance to investors, or by such other methods as recognised by the CSRC or the Shenzhen Stock Exchange; the final issuance method shall be determined by the Board in accordance with the authorisation of the general meeting and the relevant requirements of the CSRC;

Target subscribers:

Eligible strategic investors, offline investors and qualified domestic natural persons, legal persons and other investors who have opened accounts with the Shenzhen Stock Exchange (excluding persons prohibited from purchasing under national laws, regulations and normative documents), or such other target subscribers as prescribed by the CSRC or the Shenzhen Stock Exchange;

Underwriting method: standby underwriting;

Place of listing of the shares: the ChiNext Market of the Shenzhen Stock Exchange;

Timing of issuance:

The Company will proceed with the issuance after review and approval by the Shenzhen Stock Exchange and registration with the CSRC, and the specific issuance date shall be determined by the Board or its authorised persons as authorised by the general meeting after review and approval by the Shenzhen Stock Exchange and registration with the CSRC;

Use of proceeds:

After deducting the issuance expenses, the proceeds from the Offering and Listing by the Company will be invested in the following projects:

No.	Project name	Total investment amount of the project <i>(RMB ten thousand)</i>	Amount of proceeds to be invested <i>(RMB ten thousand)</i>
1	R&D upgrade and industrialisation project for full-stack intelligent solutions and services based on an enterprise-grade AI platform	259,151.45	255,000.00
2	Domestic AI information technology application innovation R&D project	51,055.71	50,000.00
3	Replenishment of working capital	75,000.00	75,000.00
	Total	385,207.16	380,000.00

Domestic Shares of the Company:

After the Offering and Listing, the Company's unlisted domestic shares will become A Shares and will be deposited with China Securities Depository and Clearing Corporation Limited, and will be subject to the lock-up restrictions under the relevant PRC laws and regulations.

Validity period of the resolution:

The resolution is valid for 12 months from the date on which it is considered and approved at the general meeting.

The A Shares will be issued under specific mandate granted by the Shareholders at the EGM for the allotment and issuance of A Shares pursuant to the A Share Offering.

This resolution was considered and approved by the Board on June 9, 2026 and will be proposed at the EGM for consideration and approval.

II. ESTABLISHMENT OF THE STRATEGY COMMITTEE OF THE BOARD

The Board hereby announces that, in order to strengthen the development of the Board and enhance the scientific decision-making of the Board, the Board has established the strategy committee of the Board in accordance with the Company Law of the People's Republic of China and other laws, regulations and normative documents. The strategy committee of the Board consists of three Directors, namely Dr. Dai Wenyuan, Mr. Chen Yuqiang and Dr. Yang Qiang, and Dr. Dai Wenyuan, a Director of the Company, shall serve as the convenor of the strategy committee of the Board.

The above matter was considered and approved by the Board on June 9, 2026.

III. PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND PROPOSED AMENDMENTS/FORMULATION OF INTERNAL GOVERNANCE POLICIES; REVISION OF RULES OF PROCEDURES OF SPECIALISED COMMITTEES UNDER THE BOARD**Proposed Amendments to the Articles of Association**

The Board hereby announces that, based on the needs of the Company for the proposed A Share Offering, pursuant to the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Guidelines for the Articles of Association of Listed Companies and other relevant laws, regulations and normative documents, and taking into account the actual circumstances and needs of the Company, the Company proposes to amend the existing Articles of Association of Phancy Group Co., Ltd. Subject to approval by the general meeting, the amended Articles of Association will take effect from the date of the Offering and Listing. Before then, the existing Articles of Association of Phancy Group Co., Ltd. will continue to be effective.

Proposed Amendments/Formulation of Internal Governance Policies

Based on the needs of the Company for the Offering and Listing, pursuant to the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Code of Corporate Governance for Listed Companies, the Rules Governing the Listing of Shares on the ChiNext Market of the Shenzhen Stock Exchange, the Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 – Standardised Operation of Companies Listed on the ChiNext Market and other relevant laws, regulations and normative documents, as well as the Articles of Association of Phancy Group Co., Ltd., and in order to better regulate corporate governance, safeguard the interests of the Company and promote the long-term development of the Company, the Company proposes to amend the Rules of Procedure for General Meetings of Phancy Group Co., Ltd., the Rules of Procedure for Board Meetings of Phancy Group Co., Ltd., the Working System for Independent Non-executive Directors of Phancy Group Co., Ltd. and the Administrative Measures for Related (Connected) Transactions of Phancy Group Co., Ltd., and to formulate the Management System for External Guarantees of Phancy Group Co., Ltd., the Management System for External Investments of Phancy Group Co., Ltd., the Management System for Proceeds of Phancy Group Co., Ltd., the Management System for Preventing Occupation of Company Funds by Controlling Shareholders, Actual Controllers and Other Related Parties of Phancy Group Co., Ltd., and the Management System for the Holding of Shares in the Company by Directors and Senior Management and Changes Thereof of Phancy Group Co., Ltd..

Among the proposed amendments/formulation of the above internal governance policies, save for the Management System for Proceeds of Phancy Group Co., Ltd. and the Management System for the Holding of Shares in the Company by Directors and Senior Management and Changes Thereof of Phancy Group Co., Ltd., which shall become effective from the date of the Offering and Listing upon the approval by the general meeting, the proposed amendments/formulation of the remaining internal governance policies shall become effective upon approval by the general meeting.

The above resolutions were considered and approved by the Board on June 9, 2026 and will be proposed at the EGM for consideration and approval by the Shareholders.

Revision of Rules of Procedures of Specialised Committees under the Board

In addition, the remuneration committee under the Board has been renamed as the remuneration and appraisal committee under the Board with effect from the date of this announcement. The Board has also approved the revisions to the terms of reference and rules of procedures of the audit committee under the Board, the nomination committee under the Board and the remuneration and appraisal committee under the Board, with effect from the date of this announcement. The revised terms of reference and rules of procedures have been published on the website of the Company and the website of the Stock Exchange.

IV. OTHER RESOLUTIONS IN RELATION TO THE PROPOSED A SHARE OFFERING

The Board also approved a series of other resolutions in relation to the proposed A Share Offering, including:

- 1) the proceeds-funded projects and their feasibility in relation to the Company's initial public offering of Renminbi ordinary shares (A Shares) and listing on the ChiNext Market of the Shenzhen Stock Exchange;
- 2) the plan for assuming the accumulated unrecovered losses before the Company's initial public offering of Renminbi ordinary shares (A Shares) and listing on the ChiNext Market of the Shenzhen Stock Exchange;
- 3) the three-year shareholder dividend return plan after the Company's initial public offering of Renminbi ordinary shares (A Shares) and listing on the ChiNext Market of the Shenzhen Stock Exchange;
- 4) the plan for stabilising the share price within three years after the Company's initial public offering of Renminbi ordinary shares (A Shares) and listing on the ChiNext Market of the Shenzhen Stock Exchange;
- 5) undertakings and binding measures in relation to the Company's initial public offering of Renminbi ordinary shares (A Shares) and listing on the ChiNext Market of the Shenzhen Stock Exchange;
- 6) measures to make up for the diluted immediate returns in relation to the Company's initial public offering of Renminbi ordinary shares (A Shares) and listing on the ChiNext Market of the Shenzhen Stock Exchange;
- 7) the proposal that the general meeting authorise the Board to handle matters relating to the initial public offering of Renminbi ordinary shares (A Shares) and listing on the ChiNext Market of the Shenzhen Stock Exchange; and
- 8) the resolution on the engagement of intermediaries.

The above resolutions were considered and approved by the Board on June 9, 2026 and will be proposed at the EGM for consideration and approval by the Shareholders.

V. REASONS FOR AND PURPOSES OF THE OFFERING AND LISTING

The Company advances the Offering and Listing of A Shares to leverage the synergistic advantages of the Hong Kong and A Share capital markets, establish a dual capital operation platform, and fully utilise the notable strengths of the A Share market, including ample liquidity, strong recognition from domestic industries and diversified financing channels, while also capitalising on the Hong Kong stock market's access to international markets and global resources, thereby enabling mutual reinforcement between capital value and business development.

The proposed A Share Offering will, on the one hand, enable the Company to raise sufficient funds for key investments in computing power infrastructure, core AI technology research and development, market channel expansion and industrial ecosystem integration, so as to continuously strengthen its technological barriers and computing power supply capabilities and support the scaled commercialisation of its core businesses such as its AI platform and APIs. On the other hand, it will help further enhance the Company's brand influence and customer trust, deepen its presence in domestic industry markets, and improve its corporate governance structure and information disclosure standards. Through an H+A dual listing structure, the Company will be able to effectively broaden its financing channels, enhance its overall competitiveness, seize opportunities arising from the development of China's artificial intelligence industry, consolidate its leading industry position and achieve long-term and steady development.

Therefore, the Directors consider that the A Share Offering is in the interest of the Company and the Shareholders as a whole.

VI. EFFECT OF THE OFFERING AND LISTING ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

For reference and illustration only, assuming that (i) an aggregate of 186,097,544 A Shares under the Offering and Listing are approved for issuance (before exercise of the over-allotment option), (ii) the H share full circulation involving the conversion of 53,157,667 Unlisted Shares into H Shares (the "**H Share Full Circulation**") is completed before completion of the Offering and Listing, (iii) save for the conversion of Unlisted Shares into H Shares under the H Share Full Circulation and the issue of A Shares under the Offering and Listing, the issued share capital of the Company remains unchanged, and (iv) the over-allotment option is exercised in full and 27,914,631 additional A Shares are issued, the shareholding structure of the Company as at the date of this announcement, immediately after completion of the H Share Full Circulation,

immediately after completion of both the H Share Full Circulation and the Offering and Listing, and immediately after full exercise of the over-allotment option is as follows:

Type	As at the date of this announcement		Immediately after completion of the H Share Full Circulation ⁽⁴⁾		Immediately after completion of the H Share Full Circulation and the Offering and Listing ⁽⁴⁾		Immediately after full exercise of the over-allotment option	
	Number of Shares	Approximate percentage of the issued Shares of the Company (%)	Number of Shares	Approximate percentage of the issued Shares of the Company (%)	Number of Shares	Approximate percentage of the issued Shares of the Company (%)	Number of Shares	Approximate percentage of the issued Shares of the Company (%)
Unlisted Shares⁽¹⁾								
Dr. Dai Wenyuan (“Dr. Dai”) ⁽²⁾⁽⁴⁾	147,177,986	26.36%	94,095,724	16.85%	94,095,724	12.64%	94,095,724	12.18%
Unlisted Shares/A Shares held by non-core connected persons ⁽⁵⁾	51,691,251	9.26%	51,615,846	9.25%	51,615,846	6.93%	51,615,846	6.68%
Newly issued A Shares under the Offering and Listing	–	–	–	–	186,097,544	25.00%	214,012,175	27.71%
Subtotal of Unlisted Shares	198,869,237	35.62%	145,711,570	26.10%	331,809,114	44.57%	359,723,745	46.58%
H Shares								
Dr. Dai ⁽³⁾⁽⁴⁾	30,029,564	5.38%	83,111,826	14.89%	83,111,826	11.17%	83,111,826	10.76%
Ungranted shares held by the Trustee	93	0.00%	93	0.00%	93	0.00%	93	0.00%
H Shares held by public holders ⁽⁵⁾	328,138,539	58.78%	328,213,944	58.79%	328,213,944	44.09%	328,213,944	42.50%
Treasury Shares	1,255,200	0.22%	1,255,200	0.22%	1,255,200	0.17%	1,255,200	0.16%
Subtotal of H Shares	359,423,396	64.38%	412,581,063	73.90%	412,581,063	55.43%	412,581,063	53.42%
Total	558,292,633	100.00%	558,292,633	100.00%	744,390,177	100.00%	772,304,808	100.00%

Notes:

- (1) Immediately after completion of the Offering and Listing, the issued Domestic Shares will be converted into A Shares.
- (2) As at the date of this announcement, Dr. Dai beneficially owned 106,164,523 Unlisted Shares and was deemed to be interested in 31,981,367, 5,052,824 and 3,979,272 Unlisted Shares held by Phancy Investment, Phancy Yinyuan and Nanjing Phancy, respectively. Pursuant to the Securities and Futures Ordinance, the spouse of Dr. Dai is also deemed to be interested in the Shares in which Dr. Dai is interested.
- (3) As at the date of this announcement, Dr. Dai was deemed to be interested in 22,936,567, 3,484,725 and 3,608,272 H Shares held by Phancy Investment, Phancy Yinyuan and Nanjing Phancy, respectively.

- (4) For the purpose of the illustration in the above table, the H Share Full Circulation assumes the conversion of 53,082,262 Unlisted Shares personally held by Dr. Dai into H Shares. Accordingly, immediately after completion of the H Share Full Circulation, the number of Unlisted Shares/A Shares attributable to Dr. Dai decreases from 147,177,986 Shares to 94,095,724 Shares, and the number of H Shares attributable to Dr. Dai increases from 30,029,564 Shares to 83,111,826 Shares.

For the purpose of the same illustration, 75,405 Unlisted Shares held by Beijing Zhonghujin No. 1 Artificial Intelligence Technology Industrial Fund Management Center (Limited Partnership) are assumed to be converted into H Shares under the H Share Full Circulation. Such conversion accounts for the corresponding decrease in the number of Unlisted Shares/A Shares held by non-core connected persons and the corresponding increase in the number of H Shares held by public holders, and does not change the total issued share capital of the Company.

- (5) As at the date of this announcement, the trustee (the “**Trustee**”) of the H share restricted share unit scheme adopted on September 19, 2024 held 93 ungranted H Shares. Such ungranted H Shares are not counted as H Shares held by public holders pursuant to Rule 8.24 of the Listing Rules. For the avoidance of doubt, the H Shares granted to employees and held by the Trustee are included in H Shares held by public holders.
- (6) The shareholding percentages may not add up to the total due to rounding.

Assuming that an aggregate of 186,097,544 A Shares are issued under the A Share Offering (before the exercise of the over-allotment option) upon approval, and that there is no change in the issued share capital of the Company prior to completion of the A Share Offering, the A Shares newly issued under the A Share Offering before exercise of the over-allotment option will represent (a) approximately 33.33% of the existing issued share capital of the Company as at the date of this announcement and (b) approximately 25.00% of the total issued share capital of the Company immediately upon completion of the A Share Offering. Assuming the over-allotment option is exercised in full and 27,914,631 additional A Shares are issued, the A Shares newly issued under the A Share Offering will represent approximately 38.33% of the existing issued share capital of the Company as at the date of this announcement and approximately 27.71% of the total issued share capital of the Company immediately after completion of the A Share Offering and full exercise of the over-allotment option.

VII. EQUITY FUND RAISING ACTIVITIES IN THE PAST TWELVE MONTHS

On April 22, 2026, the Company and the placing agents entered into a placing agreement, pursuant to which the placing agents have conditionally and severally agreed, as the placing agents of the Company, to procure, on a best effort basis, no less than six placees to subscribe for up to 38,800,000 new H Shares at the placing price of HK\$40.36 per H Share (the “**2026 Placing**”). Completion of the 2026 Placing took place on April 29, 2026 and a total of 38,800,000 new H Shares have been successfully placed by the placing agents to no less than six placees. The gross proceeds and net proceeds from the 2026 Placing were approximately HK\$1,565.97 million and HK\$1,555.63 million, respectively. For details, please refer to the announcements of the Company dated April 22, 2026 and April 29, 2026.

On July 17, 2025, the Company entered into a subscription agreement with the subscriber and a placing agreement with the placing agent in respect of the subscription, pursuant to which the subscriber conditionally agreed to subscribe for, and the Company conditionally agreed to allot and issue, a total of 25,900,000 H Shares at the subscription price of HK\$50.50 per H Share (the “**2025 Subscription and Placing**”). The subscription shares under the 2025 Subscription and Placing were allotted and issued on August 14, 2025. The gross proceeds and net proceeds from the 2025 Subscription and Placing were approximately HK\$1,307.95 million and HK\$1,306.18 million, respectively. For details, please refer to the announcements of the Company dated July 17, 2025 and August 14, 2025.

Set out below is the intended use of the net proceeds from the 2026 Placing and the 2025 Subscription and Placing respectively:

2026 Placing

The use of the proceeds from the 2026 Placing is set out below:

The intended use of the net proceeds	Allocation of net proceeds (HK\$ million)	Approximate amount of utilised net proceeds as at the date of this announcement (HK\$ million)	Approximate amount of unutilised net proceeds as at the date of this announcement (HK\$ million)
(1) 80% for advancing heterogeneous AI computing equipment based on heterogeneous GPUs, providing infrastructure for the Group’s API business	1,244.50	459.74	784.76
(2) 20% for global business expansion and potential acquisitions of technology service providers that support the emerging businesses, including embodied intelligence and smart devices	311.13	–	311.13
Total	<u>1,555.63</u>	<u>459.74</u>	<u>1,095.89</u>

2025 Subscription and Placing

The use of proceeds of the 2025 Subscription and Placing is set out in the table below:

The intended use of the net proceeds	Allocation of net proceeds (HK\$ million)	Approximate amount of utilised net proceeds as at the date of this announcement (HK\$ million)	Approximate amount of unutilised net proceeds as at the date of this announcement (HK\$ million)
(1) 50% for investment in research and development regarding artificial intelligence (AI) products and solutions	653.09	270.28	382.81
(2) 40% for global business expansion and potential acquisitions of technology service providers that support the aforementioned emerging businesses	522.47	–	522.47
(3) 10% for general corporate purpose	130.62	–	130.62
Total	<u>1,306.18</u>	<u>270.28</u>	<u>1,035.90</u>

It is expected that the unutilised net proceeds raised from the 2026 Placing and the 2025 Subscription and Placing will be deployed in accordance with the above intended usage.

As at the date of this announcement, save as disclosed above, the Company has not conducted any fund raising activities in relation to the issue of equity securities of the Company in the past twelve months immediately preceding the date of this announcement.

VIII. EGM

Reference is made to the Company's announcement dated June 8, 2026, regarding the book closure period. The Company will convene the EGM for the Shareholders to consider and, if thought fit, approve the above resolutions required to be submitted to the EGM for consideration. A circular containing details of the above resolutions, together with the notice of the EGM, will be published in due course.

IX. OTHERS

Shareholders and potential investors should note that the proposed A Share Offering is subject to review and approval by the Shenzhen Stock Exchange, registration with the CSRC and/or approval by other relevant regulatory authorities, and may or may not proceed. There is no assurance that the proposed A Share Offering will proceed and be completed successfully. Investors are advised to exercise caution when dealing in the securities of the Company. The Company will make further announcement(s) to disclose any material updates and developments in relation to the proposed A Share Offering in accordance with the Listing Rules and other applicable laws and regulations.

X. DEFINITIONS

Term	Meaning
“A Share Offering”, “Offering” or “Offering and Listing”	the proposed initial public offering of Renminbi ordinary shares (A Shares) by the Company and listing on the ChiNext Market of the Shenzhen Stock Exchange
“A Shares”	the Renminbi ordinary shares proposed to be initially publicly offered by the Company and listed on the ChiNext Market of the Shenzhen Stock Exchange
“Articles of Association”	the articles of association of the Company
“Beijing Xinzhi”	Beijing Xinzhi Linghang Management Consulting Co., Ltd., and Dr. Dai Wenyuan holds 99% of its equity as at the date of this announcement
“Board”	the board of directors of the Company
“CCASS”	the Central Clearing and Settlement System established and operated by HKSCC
“ChiNext Market”	the ChiNext Market of the Shenzhen Stock Exchange
“Company”	Phancy Group Co., Ltd. (範式智能技術集團股份有限公司), whose H Shares are listed on the Main Board of the Stock Exchange (stock code: 6682)
“CSRC”	China Securities Regulatory Commission
“Director(s)”	the director(s) of the Company
“EGM”	the 2026 second extraordinary general meeting of the Company to be held on June 26, 2026, or any adjournment thereof

Term	Meaning
“Group”	the Company and its subsidiaries
“H Shares”	overseas listed foreign shares of RMB1.00 each in the share capital of the Company, which are subscribed for and traded in Hong Kong dollars and listed on the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Nanjing Phancy”	Nanjing Phancy Enterprise Management Consulting Partnership (Limited Partnership), an employee incentive platform of the Company, and Beijing Phancy Xinzhi Enterprise Management Co., Ltd. (Beijing Xinzhi’s wholly owned subsidiary) is the general partner of Nanjing Phancy
“Phancy Investment”	Phancy (Tianjin) Management Consulting Partnership (Limited Partnership) , an employee incentive platform of the Company, and Beijing Xinzhi is the sole general partner of Phancy Investment
“Phancy Yinyuan”	Tianjin Phancy Yinyuan Management Consulting Partnership (Limited Partnership), and Beijing Xinzhi is the sole general partner of Phancy Yinyuan
“RMB”	Renminbi, the lawful currency of the PRC
“Shares”	ordinary shares of RMB1.00 each in the share capital of the Company
“Shareholders”	holders of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Treasury Shares”	has the meaning ascribed to it under the Listing Rules

Term	Meaning
“Unlisted Shares” or “Domestic Shares”	ordinary shares of RMB1.00 each issued by the Company, which are not listed on any stock exchange as at the date of this announcement
“%”	per cent

By order of the Board
Phancy Group Co., Ltd.
 範式智能技術集團股份有限公司
Dr. Dai Wenyuan
Chairman and Executive Director

Hong Kong, June 9, 2026

As at the date of this announcement, the Board comprises executive Directors Dr. Dai Wenyuan and Mr. Chen Yuqiang; non-executive Directors Dr. Yang Qiang, Mr. Dou Shuai and Mr. Zhang Jing; independent non-executive Directors Mr. Li Jianbin, Mr. Liu Chijin, Ms. Ke Yele and Mr. Pan Jialin; and employee representative Director Mr. Chai Yifei.